<DOC>
	<DOCNO>NCT02194764</DOCNO>
	<brief_summary>The purpose study develop cost-effective breath-based medication adherence monitoring system monitor whether recover opiate addict actually take specific treatment medication call naltrexone .</brief_summary>
	<brief_title>An Adherence Tool Manage Narcotic -Addicted HIV Patients</brief_title>
	<detailed_description>This study two part . In first part create eight SMART capsule-based naltrexone system use 4 general type pharma formulation strategy . Model naltrexone ( 50mg ) formulation contain GRAS taggant , 2-butanol ( 40 80 mg ) prepare preliminary stability study execute . Type 1 hydrophobic system , Type 2 hydrophilic system , Type 3 reverse micelle system Type 4 water-in-oil microemulsion system . All formulation prepare use USP-grade excipients , 2-butanol , naltrexone base naltrexone HCl . Naltrexone HCl significant water solubility use preparation formulation type 2 4 , whereas lipid soluble free base naltrexone use formulation type 1 3 . Manufacturer 's specification supply Capsugel use determine compatibility capsule material propose excipients , guide capsule selection ( gelatin HPMC ) .Prepared formulation characterize particle size analysis analyze determine actual concentration naltrexone 2-butanol . Particle size accomplished dynamic light scatter use 90Plus particle size analyzer . With formulation type 1 2 , technique demonstrate homogeneity mixture absence particulate . With type 3 4 , particle size distribution measure confirm presence monodisperse reverse micelle nanoscale droplet . The concentration naltrexone final formulation verify Liquid chromatography-mass spectrometry ( LC-MS ) /or Ultra Performance Liquid Chromatography ( UPLC ) . The concentration 2-butanol determine gas chromatography-Mass Spectrometry ( GC-MS ) . Following initial characterization , formulation store sealed vial place ICH standard stability condition test weekly interval 1 , 3 6 month . The three outstanding formulation candidate select use part two study . In second part three formulation select meet criterion stability , solubility , particle size , color concentration 2-butanol first part study . Each formulation prepare certified pharmacy . In addition three select naltrexone formulation , fourth dosage form , capsule-in-capsule ( CIC ) design , prepared pharmacy incorporate 40 80 mg ( determine first part study ) 2-butanol encapsulate ( size 3 capsule ) plus 50 mg naltrexone ( HCI form ) size 0 double blind hard gel capsule . This capsule-in-capsule design serve formulation-free positive control . Note : All naltrexone formulation , administer human subject , contain quantity excipients/components already designate FDA safe ( e.g. , inactive ingredient list , permissible daily exposure [ PDE ] , GRAS/direct food additive designation ) .</detailed_description>
	<mesh_term>Narcotics</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Ability understand provide write informed consent Subject least 18 Years Age Subject must willing comply study procedure &lt; 18 year Subject history opioid use disorder current chronic opioid therapy recent ( past week ) acute opioid therapy , currently pregnant contraindication naltrexone use per FDA label .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>